Treatment Program for PTSD
We are building upon successful foundational research that established a successful cure for PTSD in a rodent model. This piloted PTSD treatment in rodents consisted of a surgical intervention shortly after a traumatic event to decrease GluA1 levels, and therefore functional AMPA receptors, in the amygdala to non-PTSD levels. Testing in the rodent model effected a complete reversal of PTSD without amnesia for the triggering trauma.
We are now developing a non-invasive oral treatment for PTSD. Unlike existing PTSD treatments, which typically temporarily suppress symptoms, we target the biological cause of PTSD—an up-regulation of a receptor protein in the region of the brain responsible for fear learning. Our small molecule drug discovery program began in Spring 2017, with hit-to-lead evaluation expected for late 2018.